The Prostate

Prostate cancer cells with low androgen receptor and high cell movement traits are sensitive to drugs blocking NAD+ production

Updated

Abstract

The treatment-resistant prostate cancer cells exhibit a NAPRT-low phenotype associated with enzalutamide resistance.

  • AR-low treatment-resistant tumor cells show significantly different gene expression patterns compared to treatment-sensitive cells, indicating an EMT-high expression phenotype.
  • These resistant cells lack adequate levels of NAPRT, an enzyme crucial for NAD+ production, leading to their vulnerability to inhibitors targeting NAD+ biosynthesis.
  • Exploiting this vulnerability may enhance the effectiveness of enzalutamide in treating prostate cancer.
  • The association of NAPRT deficiency with the AR-low/EMT-high phenotype has been observed in both subpopulations of tumor cells and clinical patient samples.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free